ClinicalTrials.gg
RecruitingNCT06655272OM85OLDERUpdated Mar 18, 2025

OM 85 to Prevent Respiratory Infections in Older At Risk Patients

A Phase 4 interventional study of Bacterial Lysate and Placebo in Respiratory Tract Infections (RTI), sponsored by Campus Bio-Medico University. Recruiting at 1 site in Italy. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2025-03-18.

Sponsored by Campus Bio-Medico University · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Respiratory Tract Infections with a site in Italy — 11 open to participants now, 13 under way, 2 of them phase 3. Respiratory Tract Infections · Italy.

Planned enrollment
9th of 23
360 · median 252
Started
2025
with 4 others
Phase 4
5 of 34
2 open now
Primary completion
2026-01
later than 3 of 12 live
Registered
27th of 34
by date
Lead sponsor
1 of 34
Campus Bio-Medico University

Among the 34 studies in Respiratory Tract Infections with a site in Italy, this one is the 9th largest by planned enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2025, is one of 5 in phase 4, reaches primary completion later than 3 of the 12 other live ones, and was the 27th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

11 of the 34 studies in Respiratory Tract Infections with a site in Italy are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 73 Respiratory Tract Infections studies recruiting now, 33 (45%) set no upper age limit and 32 (44%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Respiratory Tract Infections with a site in Italy, or all of them as a file.
02

Study summary

People living in NH are at higher risk of respiratory infections compared to their counterpart living in the community. Products obtained from dead bacteria ("bacterial lysate") can be used to boost immune system and may reduce the risk of respiratory infections. Very little information is available on the effect of these substances in older people. This study will evaluate the efficacy of a bacterial lysate in reducing the incidence of lower respiratory tract infections in older people living in nursing homes. The study will include a treatment arm, in which participants will received the lysate, and a control arm in which participants will received a matching placebo (i.e., a pill that has the same appearance of the lysate but does not contain the lysate itself).

Read the detailed description

OM 85 (lyophilized bacterial lysate) proved effective in increasing the immune response against bacteria in animal models. Furthermore, its use was shown to be associated with lower incidence of RTIs in children and at risk adults. However, there is a paucity of information about OM 85 efficacy in the elderly, i.e., in a population which, due to immunosenescence and multimorbidity, might have a distinctive response to this immunostimulating strategy. Indeed, the only study properly designed for a geriatric population is a randomized controlled trial on 290 people over-65 with chronic bronchitis and frequent exacerbations; here, a significant decrease in the incidence of acute bronchitis was observed in the OM 85 group over 6 months (Orcel B et al. Eur Respir J, 1994, 7, 446-452). However, this population seems poorly representative of the average older population at risk of RTI. Indeed, chronic diseases like congestive heart failure and chronic renal failure qualified as exclusion criteria. Furthermore, a history of at least 4 episodes of acute bronchitis treated with antibiotics in the 6-month reference period of the previous year were requested for the enrollment. Thus, the study population is unlikely to reflect the profile of risk of the elderly and frail population, which is characterized by a high prevalence of chronic diseases, but not by such a high incidence of respiratory infections. Indeed, even in severe COPD the frequency of exacerbations rarely exceeds 2 yearly and is rapidly declining (Andreas et al. Respiratory Research (2019) 20:186). Geriatric patients are variably represented in other studies which proved the efficacy of OM 85 in adult populations with COPD or chronic bronchitis. Twelve studies met the quality criteria to be eligible for a recently published meta-analysis (Huang Y, Pei Y, Qian Y, Yao Z, Chen C, Du J, Shi M, and Zhou T, 2022. A meta-analysis on the efficacy and safety of bacterial lysates in chronic obstructive pulmonary disease. Front. Med. 9:877124. doi: 10.3389/fmed.2022.877124). However, elderly patients and especially those over 75, the most vulnerable to respiratory infections, were a minority of probands. Furthermore, the selection criteria pointed at COPD as the main disease in the vast majority of the studies. IMP has never been tested in an older population with a heavy burden of multimorbility and frailty and a high risk of RTI, I e in the population most likely to benefit from it. Accordingly, this trial is expected to clarify what previous studies could not because they were not designed to study this kind of population, and only sparse and partial information could be derived by picking selected patients from the study populations. Furthermore, all our patients will receive the recommended vaccines, and this will allow test IMP in a framework free from confounding by heterogeneity in vaccine policy.

Primary objective:

To evaluate whether and to which extent OM85 compared with placebo is able to reduce respiratory tract infections (RTIs) over a 12-month period in a population of subjects aged 75 years and older, residing in nursing homes, and with a history of at least two RTIs in the 12 months prior to enrollment.

Secondary objectives:

To verify whether the rate of hospital admissions and emergency department visits due to RTI decreases from the previous year differently in the OM 85 group compared with placebo.

Evaluate the number of antibiotic prescriptions between the two groups (OM 85 and placebo) during the 12-month study period.

Describe the demographic, clinical and functional characteristics of patients with higher RTI numbers.

Evaluate the incidence of treatment-emergent adverse events (TEAEs).

03

Conditions studied

  • Respiratory Tract Infections (RTI)

Keywords

  • Older people
  • Nursing home
  • Bacterial lysate
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 75 years or older
  • At least 2 RTIs in the year prior to enrollment
  • Patients must have been residing in nursing homes for at least 6 months and have an estimated length of stay in nursing homes of at least 6 months by their treating physician.
  • Signed . If participants are unable to provide informed consent due to cognitive impairment, consent will be provided by a legally recognized representative or trustee of the patient (pursuant to Article 4 of Law No. 219 of December 22, 2017).
  • Have a of at least one year in the judgment of their treating physician.

Exclusion criteria

Exclusion Criteria:

  • Patients with known allergy or previous intolerance to any component (including the ) of the study drug
  • Patients with active neoplasia and prognosis of less than one year
  • Patients with previous organ transplantation
  • Patients treated with prohibited drugs (see Table 1) in the 3 months prior to the start of the study
  • Patients who have taken bacterial lysates in the 6 months prior to enrollment or are currently using them
  • Patients regularly treated with oral
  • Patients unable to follow instructions and unreliable patients (including patients with alcoholism or patients unwilling to give or comply with protocol requirements)
  • Patients with any other clinical condition that, in the opinion of the investigator, would not allow completion of the protocol and safe administration of the study drugs
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Intervention

    Bacterial lysate p.o. administered for two three-months cycles.

    Drug: Bacterial Lysate

  • Placebo comparator
    Control

    Matching placebo.

    Drug: Placebo

Interventions

  • DrugBacterial Lysate

    Administration p.o. for 10 days per month for 3 months, two consecutive cycles.

  • DrugPlacebo

    Matching placebo.

06

What researchers measure

Primary outcomes

  1. Incidence of lower respiratory tract infections.

    New cases of clinically-diagnosed lower respiratory tract infections

    Time frame: 12 months

Secondary outcomes

  1. Rate of hospitalizations and emergency room admissions

    Rate of hospitalizations and emergency room admissions due to respiratory tract infections.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jan 2026, 11 months after the start.

Of 29 phase 4 interventional studies under Respiratory Tract Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 51. This study's planned 11 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2024
First posted
Oct 23, 2024
StartActual
Feb 1, 2025
Primary completionEst.
Jan 2026
CompletionEst.
Apr 2026
Last update
Mar 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06655272
Lead sponsor
Campus Bio-Medico University
Collaborators
OM Pharma SA
Responsible party
Raffaele Antonelli Incalzi (Professor, Campus Bio-Medico University) — Principal investigator
First posted
Oct 23, 2024
Start date
Feb 1, 2025
Primary completion
Jan 2026 (estimated)
Completion
Apr 2026 (estimated)
Last update
Mar 18, 2025

Study contacts

Silvia Travaglini, MD
Contact
silvia.travaglini@unicampus.it
+39 06 22541 ext. 1

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion